Instituto de Investigación Sanitaria Fundación para la Investigación del Hospital Clínico de Valencia-ko ikertzaileekin lankidetzan egindako argitalpenak (2)

2024

  1. AntimiR treatment corrects myotonic dystrophy primary cell defects across several CTG repeat expansions with a dual mechanism of action

    Science advances, Vol. 10, Núm. 41, pp. eadn6525

2021

  1. Preclinical characterization of antagomiR-218 as a potential treatment for myotonic dystrophy

    Molecular Therapy - Nucleic Acids, Vol. 26, pp. 174-191